TABLE 6.

Independent predictors of negative T‐spot post second vaccination in myeloma patients only

Predictor	Model 1 (n = 157)		Model 2 (n = 105)		Model 3 (n = 68)
	Odds ratio	95% CI	Odds ratio	95% CI	Odds ratio	95% CI
Age (year)	1.04	1.01–1.09	1.03	0.98–1.09	1.04	0.97–1.11
Female sex	0.84	0.43–1.64	1.05	0.43–2.60	1.06	0.32–3.77
Time between vaccine doses (weeks)	1.02	0.85–1.64
Time from second vaccine dose and sample (weeks)	0.98	0.89–1.07
Oxford/AstraZeneca vacccine a			0.27	0.11–0.69	0.29	0.08–1.01
Myeloma status ‐partial response/stable b			2.88	1.04–7.97	2.41	0.67–8.73
Myeloma status ‐progression/relapse b			2.30	0.76–6.96	0.93	0.13–6.52
CD38/BCMA c					4.80	1.09–21.02
Other chemo c					1.21	0.31–4.70
Pseudo‐R2	0.08		0.12		0.15

^a Pfizer‐BioNTech is comparator.

^b Complete remission/very good partial response is comparator.

^c No chemotherapy is comparator.

Bold indicates statistically significant.